Please assess the completion status of the following clinical trial:

Trial Title: Dolutegravir Plus Tenofovir/Lamivudine or Emtricitabine in HIV-1 Infected Transgender Women

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. HIV-1 positive serology by at least two different serological tests (rapid test, ELISA, Western Blot) or a viral load higher than 3,000 copies/mL.~2. 18 years and older.~3. Self-identified as TGW~4. ART naïve.~5. Written informed consent provided.~Exclusion Criteria:~1. Genotypic resistance to TDF and/or FTC as per IAS-USA resistance panel 2013.~2. Alcohol or drug use that might affect adherence.~3. Concomitant use of lipid-lowering drugs, interferon, interleukin-2, cytotoxic chemotherapy, dofetilide (or pilsicainide) or immunosuppressors, antacids drugs containing Ca++ and or Mg++ at study entry.~4. Opportunistic infection (CDC C category) or other disease and/or clinical conditions that, in the investigator's opinion, would compromise the patient's safety or outcome of the study; including malignancy other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or non-invasive cutaneous squamous cell carcinoma, or cervical intraepithelial neoplasia.~5. Treatment with any of the following agents within 28 days of screening: radiation therapy; cytotoxic chemotherapeutic agents; any immunomodulators that alter immune responses or treatment with an HIV-1 immunotherapeutic vaccine within 90 days of screening or exposure to an experimental drug or experimental vaccine within either 28 days, 5 half-lives of the test agent, or twice the duration of the biological effect of the test agent, whichever is longer, prior to the first dose of the investigational product.~6. Contraindication to any of the study drugs (history of renal diseases, lab abnormalities grade 4 or any other clinical condition prior therapy that, in the opinion of the investigator, would make the subject unsuitable for the study or unable to comply with the dosing requirements).~7. Anticipated need for Hepatitis C virus (HCV) therapy during the study.~8. Creatinine clearance of \<50 mL/min via Cockroft-Gault method.~9. Subjects with moderate to severe hepatic impairment (Class B or greater) as determined by Child-Pugh classification.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- single arm (Type: EXPERIMENTAL): ARV treatment based on Dolutegravir Plus Tenofovir/Lamivudine or Emtricitabine

Based on this trial design, predict the completion outcome and termination type (if applicable).